Should we enter, and on what conditions?
- Compare opportunity, risk and capital across entry routes
- Identify assumptions that could reverse the decision
- Set evidence gates for establishment and launch
Europe → Nigeria · Healthcare & Life Sciences
Nigeria market entry for healthcare and life sciences
Prioritise the right products, registration pathway, distributor and service model for a safe, commercially viable Nigerian healthcare launch.
Geographic corridorEurope → Nigeria
Selected Delivery · anonymised
This page presents a selected delivery situation without naming the organisation or publishing unsupported quantitative results. Applicability is confirmed for the client’s actual product, transactions and locations.
Who this is forA route for a defined
A route for a defined
buyer and decision.
For diagnostics, medical-device, digital-health and life-sciences companies deciding which products to register, which channel to use and how to maintain quality after import.
What must be ready before launch?
- Translate requirements into owners and evidence
- Coordinate partner, product, people and operating workstreams
- Track readiness, issues, decisions and benefits
Corridor architectureSee the route before
See the route before
committing the resources.
The diagram connects the source-market position to the target-market operating route. It is then converted into named evidence, owners and launch gates.
Geographic corridorEurope → Nigeria
Illustrative route mapGate 01 · Invest / deferGate 02 · Partner / establishGate 03 · Pilot / launchGate 04 · Scale / remediate
Commercial and regulatory problemsThe questions that can
The questions that can
change the entry decision.
Each issue is tested against the proposed transaction flow and operating model—not treated as a generic country checklist.
Product registration
The portfolio contained multiple device and IVD classes; a blanket launch would multiply NAFDAC evidence, cost and lead-time exposure.
Distributor dependence
Commercial reach, importer responsibilities, storage, installation, training, adverse-event reporting and cash collection would sit across several parties.
Landed cost and working capital
FX, duties, registration, minimum orders, cold-chain or storage requirements and hospital payment cycles threatened affordability and margin.
Quality and data
Post-market surveillance, complaints, service records and patient or laboratory data flows required controls that continued after product registration.
Finaffairs' workFrom evidence
From evidence
to an executable route.
Workstreams combine analysis, decision support and implementation design. Outputs are built for use by the board and the team that must deliver.
Portfolio prioritisation
Scored products by clinical demand, buyer segment, evidence readiness, registration complexity, landed margin and service burden.
- SKU prioritisation model
- Buyer and use-case map
- Registration wave plan
Regulatory and quality pathway
Mapped manufacturer and importer documentation, labelling, quality-system, registration, variation and post-market obligations to each priority SKU.
- Product compliance register
- Evidence dossier index
- Post-market RACI
Distributor and service diligence
Assessed coverage, tender access, regulatory capability, warehousing, engineering support, training, ethics, cash collection and management information.
- Distributor scorecard
- Due-diligence report
- Contract requirements
Pilot economics and mobilisation
Built landed-cost and working-capital scenarios and designed a private hospital/laboratory pilot with training, service, complaints and evidence gates.
- Pilot business case
- Pricing corridor
- 180-day launch and quality plan
Illustrative delivery prototypeOne board view of
One board view of
four connected workstreams.
This prototype demonstrates the structure of the engagement control board. Client versions contain the approved evidence, decisions, owners, dependencies and dates for the selected corridor.
Nigeria MARKET-ENTRY BOARD
Healthcare & Life Sciences · Europe → Nigeria
Prototype · illustrative fieldsHealthcare & Life Sciences · Europe → Nigeria
Portfolio prioritisation
SKU prioritisation model
Regulatory and quality pathway
Product compliance register
Distributor and service diligence
Distributor scorecard
Pilot economics and mobilisation
Pilot business case
Decision: Enter through a qualified distributor and named local importer, register a limited first wave of priority diagnostic products, and validate demand and service performance with selected private laboratories and hospitals before public-procurement expansion.Control: proceed only when agreed evidence gates are met
Selected Delivery
Priority-SKU entry for a European diagnostics business
Europe → Nigeria
Entry decision / implementation outcome
Enter through a qualified distributor and named local importer, register a limited first wave of priority diagnostic products, and validate demand and service performance with selected private laboratories and hospitals before public-procurement expansion.
Why this route
The route controlled irreversible cost while creating direct evidence on customer demand, regulatory readiness, partner performance and operational delivery.
Detailed client benefitsValue realised through
Value realised through
better sequencing and control.
Benefits are expressed qualitatively because commercially sensitive financial and performance values are not published without client approval.
Lower registration waste
Resource was concentrated on products with credible demand, documentary readiness and supportable economics.
Clearer distributor accountability
Regulatory, sales, storage, training, service, complaint and post-market duties were converted into measurable contract obligations.
More reliable pricing
The commercial model captured full landed cost, FX sensitivity, service costs, payment terms and working-capital demand.
Safer launch
Installation, user training, technical support, incident escalation and traceability were built into the pilot design.
Evidence for scale
Pilot gates created a record of adoption, service performance, margin and quality issues before widening the product portfolio.
Protected reputation
Product claims, data handling and post-market reporting were aligned with the client’s global quality framework.
Complete readinessSix modules integrated
Six modules integrated
into this market route.
Establishment, workforce, IP, contracts, product compliance and financing are connected to the same commercial decision and launch timetable.
Product registration and labelling
Requirement, owner, evidence, sequence and decision gate documented for the selected route.
Distributor and importer contracts
Requirement, owner, evidence, sequence and decision gate documented for the selected route.
Quality and post-market controls
Requirement, owner, evidence, sequence and decision gate documented for the selected route.
Data protection and digital health
Requirement, owner, evidence, sequence and decision gate documented for the selected route.
Working capital and trade finance
Requirement, owner, evidence, sequence and decision gate documented for the selected route.
Clinical training and service workforce
Requirement, owner, evidence, sequence and decision gate documented for the selected route.
Relevant leadershipNamed practitioners
Named practitioners
for this corridor.
The engagement team is shaped by the decision, jurisdiction and specialist work required.
Dr Kazeem Salaam
Market strategy, finance, regulated operating models and implementation governance across the UK, Europe and Africa.
View full profile →Kelvin Abaja
Data protection, analytics, digital controls, AI risk and cross-jurisdiction assurance readiness.
View full profile →Decision-grade insightWhat we test
What we test
before commitment.
Primary sources establish the formal baseline; interviews, financial analysis, partner diligence and operating evidence determine what it means for the client.
Relevant insights
- Registration strategy should follow product prioritisation, not precede it.
- Distributor reach is insufficient without quality, service and data controls.
- Landed cost and working capital determine whether adoption can be sustained.
Begin with the decisionWhat are you deciding,
What are you deciding,
and by when?
Share the target market, product, buyer, current route, decision deadline and the assumptions you most need to validate. We will propose a focused first scope.
Start a market-entry conversation →Contact FinaffairsInitial discussion · Scoping note · Evidence request · Mobilisation plan